These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32745802)

  • 1. An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy.
    Acar NP; Tuncer A; Ozkazanc D; Ozbay FG; Karaosmanoglu B; Goksen S; Sayat G; Taskiran EZ; Esendagli G; Karabudak R
    J Neuroimmunol; 2020 Oct; 347():577353. PubMed ID: 32745802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.
    Schwichtenberg SC; Wisgalla A; Schroeder-Castagno M; Alvarez-González C; Schlickeiser S; Siebert N; Bellmann-Strobl J; Wernecke KD; Paul F; Dörr J; Infante-Duarte C
    Neurotherapeutics; 2021 Jul; 18(3):1783-1797. PubMed ID: 34244929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.
    Saraste M; Irjala H; Airas L
    Neurol Sci; 2007 Jun; 28(3):121-6. PubMed ID: 17603762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD3
    Tahrali I; Kucuksezer UC; Akdeniz N; Altintas A; Uygunoglu U; Aktas-Cetin E; Deniz G
    Immunol Lett; 2019 Dec; 216():63-69. PubMed ID: 31589897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
    Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
    J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    Hjorth M; Dandu N; Mellergård J
    PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    Chitnis T; Arnold DL; Banwell B; Brück W; Ghezzi A; Giovannoni G; Greenberg B; Krupp L; Rostásy K; Tardieu M; Waubant E; Wolinsky JS; Bar-Or A; Stites T; Chen Y; Putzki N; Merschhemke M; Gärtner J;
    N Engl J Med; 2018 Sep; 379(11):1017-1027. PubMed ID: 30207920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies.
    Cordiglieri C; Baggi F; Bernasconi P; Kapetis D; Faggiani E; Consonni A; Andreetta F; Frangiamore R; Confalonieri P; Antozzi C; Mantegazza R
    Clin Immunol; 2016 Dec; 173():133-146. PubMed ID: 27720845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
    Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
    Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    Abdel-Dayem MA; Shaker ME; Gameil NM
    J Neuroimmunol; 2019 Dec; 337():577062. PubMed ID: 31521828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade.
    Mehling M; Burgener AV; Brinkmann V; Bantug GR; Dimeloe S; Hoenger G; Kappos L; Hess C
    Scand J Immunol; 2015 Nov; 82(5):460-6. PubMed ID: 26285786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
    Kalincik T; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Lechner-Scott J; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Solaro C; Grand'Maison F; Hupperts R; Prevost J; Sola P; Ferraro D; Terzi M; Butler E; Slee M; Kermode A; Fabis-Pedrini M; McCombe P; Barnett M; Shaw C; Hodgkinson S; Butzkueven H;
    Mult Scler; 2018 Oct; 24(12):1617-1626. PubMed ID: 28857680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response.
    García-León JA; López-Gómez C; Orpez-Zafra T; Reyes-Garrido V; Marín-Bañasco C; Oliver-Martos B; Fernández O; Leyva L
    CNS Drugs; 2014 Jun; 28(6):559-70. PubMed ID: 24599774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
    J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
    Fujii C; Kondo T; Ochi H; Okada Y; Hashi Y; Adachi T; Shin-Ya M; Matsumoto S; Takahashi R; Nakagawa M; Mizuno T
    Sci Rep; 2016 Oct; 6():35314. PubMed ID: 27752051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.